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ABSTRACT
Objective: The objective of this study is to evaluate the antihypertensive drug usage and dosage differences between geriatric and non-geriatric 
diabetics with reference to the duration of hypertension and creatinine clearance (Crcl).
Methods: In this observational study, patients with type 2 diabetes mellitus were grouped into geriatric (age ≥60 years) and non-geriatric 
(age <60 years). Patients’ demographic data, duration of hypertension, drugs prescribed, and serum creatinine were recorded after the patients 
had a stabilized antihypertensive dose for 6 months. Crcl was calculated using Cockcroft–Gault formula. The dosages of antihypertensives were 
converted into equivalent doses for easy comparison within a group. For angiotensin-converting enzyme inhibitors (ACEIs), enalapril was considered 
as prototype, and for angiotensin receptor blockers (ARBs) losartan, beta-blocker atenolol, and calcium channel blockers (CCBs), amlodipine was 
considered as prototype. Univariate analysis was done for comparison of drug doses between groups.
Results: A total of 336 diabetics with hypertension were included, of which 252 were geriatric and 84 non-geriatric. Duration of hypertension was 
expectedly longer in the geriatric group (8.40±7.26 vs. 5.46±5.67; p=0.001). Systolic blood pressure was higher in geriatrics (137.14±13.51 vs. 
133.38±12.49; p=0.01). When adjusted for the duration of hypertension and Crcl, there were no significant differences in the mean converted 
equivalent doses of beta-blockers, CCBs, ARBs, and hydrochlorothiazide between geriatrics and non-geriatrics. However, statistically significant lower 
converted equivalent doses of all ACEIs were needed in geriatrics compared to non-geriatrics, when adjusted for duration of hypertension and Crcl. 
Enalapril required 20.57% and ramipril required 18.36% dose reduction in geriatrics compared to non-geriatrics.
Conclusion: A 20% dosage reduction is needed for ACEIs in the elderly.
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INTRODUCTION
India, the world diabetes capital in the next 30 years, may also be the 
world hypertension capital [1]. Hypertension and diabetes mellitus 
(DM) are both important contributory factors for the growing burden of 
cardiovascular and chronic kidney disease [2]. Concomitant hypertension 
doubles total mortality and stroke risk, triples the risk of coronary heart 
disease, and significantly hastens the progression of microvascular 
complications, including diabetic nephropathy among diabetics [3]. 
Cardiovascular disease is the major cause of death in patients with DM. 
By 60 years, about two-thirds of hypertensives have isolated systolic 
hypertension (ISH); by 75 years, almost all hypertensives have ISH [4]. 
ISH is related strongly to the development of micro- and macrovascular 
diseases in patients with DM [5]. The incidence of hypertension increases 
with duration of type 2 diabetes; however, a substantial number of 
patients have hypertension at the time of diabetes diagnosis [6]. 
Observational studies have shown that the risk of diabetes complications 
significantly decreases with lower blood pressure, with the lowest 
risk in patients with systolic blood pressure (SBP) <120 mmHg [7]. 
Treatment of hypertension in DM is not always easy as confusion prevails 
regarding definition, target blood pressure, use of specific agents such as 
angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor 
blockers (ARBs), thiazide diuretics, calcium channel blockers (CCBs), 
beta-blockers, and their adverse effects, especially in the elderly.
Age-related changes in kidney and liver function are the most important 
physiological changes of the human body which require adjustment of 
drug selection and dosage. The impact of diabetes on renal impairment 
worsens with increasing age [8]. The progressive decline in renal 
function that occurs with age may result in the slower elimination of 
drugs that are partially or completely cleared by kidneys, leading to 
toxicity and additive side effects when dosages are not adjusted [9]. 
Dosage also depends on the duration of hypertension; longer duration 
usually requires higher doses among the elderly. Hence, there is a 
dilemma in the selection of dosage of antihypertensives among the 
elderly; renal impairment forcing lower doses while longer duration 
and poor control necessitating higher doses.
Individually tailored therapeutic strategies are needed, which may have 
less stringent targets, for which the use of common drugs should be 
critically evaluated [10]. Evaluation of the morbidity profile among 
elderly people and the impact of age and chronic conditions on 
functional disability and psychological well-being are an essential part 
of the comprehensive assessment of the elderly. Such evaluations will 
have implications for providing better health care for the elderly.
For a majority of drugs, exact dosing guidelines for geriatric patients 
have not been established and most references do not specifically 
address the use of medications in the elderly. There is a clear need to 
focus greater attention on the unique needs of elderly diabetes patients 
and individualizing care. Hence, the present study was planned to 
evaluate the antihypertensive drug usage and dosage differences 
between geriatric and non-geriatric diabetics with reference to the 
duration of hypertension and Crcl.
© 2018The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i12.29181
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METHODS
A prospective observational study was conducted for 6 months in a tertiary 
care teaching hospital after obtaining approval from the Institutional 
Ethics Committee. A written informed consent was obtained from all 
participants. All diabetic patients with hypertension were included in the 
study and were grouped into geriatric (age ≥60 years) and non-geriatric 
(age <60 years). Patients were followed up for 6 months to monitor their 
antihypertensive drug dosage. Patients who needed frequent drug dosage 
changes due to repeated acute illness or poor blood pressure control 
were not enrolled in the study. Drug treatment was not altered during 
the 6 months’ follow-up period. The prescriptions of these patients were 
analyzed and the investigators did not interfere with the dose and their 
titration. Patients’ demographic data, duration of hypertension, drugs 
prescribed, and serum creatinine were recorded. Crcl was calculated 
using Cockcroft-Gault formula. The dosages of antihypertensives were 
converted into equivalent doses for easy comparison within a group 
(Table 1). For ACEIs, enalapril was considered as prototype; for ARBs, 
losartan as prototype; for beta blockers, atenolol as prototype; and for 
CCBs, amlodipine as prototype [11].
Statistical analysis
Demographics, duration of disease, drug doses, and laboratory 
parameters were done using descriptive statistics. Students’ unpaired 
t-test was used to compare the different parameters between the two 
groups. Univariate analysis was done for the comparison of drug doses 
of two groups adjusted for the duration of hypertension and Crcl. All the 
analyses were done at 5% significance.
RESULTS
A total of 336 diabetic hypertensive patients were included in the study 
(252 geriatrics and 84 non-geriatrics). Of the 252 geriatrics, 125 were 
males, and among the non-geriatrics, 38 were males. Demographic data 
and blood pressure values of both groups are given in Table 2. SBP was 
higher in geriatrics and diastolic blood pressure (DBP) was higher in 
non-geriatrics, and the differences were clinically insignificant.
Distribution of individual antihypertensive agents between geriatrics 
and non-geriatrics did not show any significant difference (Table 3).
As shown in Fig. 1, there was no significant difference between the 
groups with respect to usage of antihypertensive drug combinations. 
The most commonly used combination was ACE inhibitors with beta-
blockers and/or thiazide diuretics (35.61%).
Table 4 shows the antihypertensive doses received by patients. Doses 
of beta-blockers (metoprolol, atenolol) received by geriatrics were 
higher than non-geriatrics but not statistically significant. Doses of 
ACE inhibitors and hydrochlorothiazide received by geriatrics were 
lower than non-geriatrics but statistically insignificant. The doses of 
bisoprolol, nifedipine, and telmisartan were not compared between the 
groups as the sample size was too small, but they were considered for 
mean converted equivalent doses.
There were no significant differences in the mean converted equivalent 
doses of beta-blockers, CCBs, ARBs, and hydrochlorothiazide when 
adjusted for the duration of hypertension and Crcl in geriatrics and 
non-geriatrics (Table 5).
Table 6 gives a comparison of the duration of hypertension and Crcl 
adjusted mean doses of enalapril and ramipril which were lower 
in geriatrics but were not significant as the sample size was small. 
Statistically significant lower converted equivalent doses of all ACE 
inhibitors were seen in geriatrics compared to non-geriatrics, indicating 
that the dose of ACE inhibitor is nearly 1.5 mg lower in geriatric 
population which is statistically and clinically significant.
DISCUSSION
Duration of hypertension was expectedly longer in the geriatric 
group. Geriatric diabetics had significantly high SBP compared to non-
geriatrics, while non-geriatrics had higher diastolic blood pressure 
although this was clinically and statistically insignificant. This increased 
systolic hypertension in the elderly which occurs with aging results 
from stiffening of the major capacitance arteries [12].
The choice of antihypertensive agents in diabetics is based on previous 
medication history, comorbid conditions as well as propensity of 
Fig. 1: Use (%) of antihypertensive drug combinations
Table 1: Equivalency chart for antihypertensive agents
Prototype Equivalent dosage of antihypertensive agents
Atenolol 50 mg Metoprolol 100 mg; Bisoprolol 5 mg; Nadolol 
40 mg
Enalapril 5 mg Ramipril 2.5 mg; Captopril 12.5 mg; 
Lisinopril 10 mg
Losartan 25 mg Telmisartan 40 mg; Irbesartan 75 mg; 
Candesartan 8 mg
Amlodipine 2.5 mg Nifedipine 30 mg
Table 2: Comparison of demographics and blood pressure 






Age (years) 68.80±6.01 51.78±6.04 0.001**
Body mass index 24.78±3.81 25.89±4.11 0.003**
Duration of DM (years) 12.04±9.08 7.23±6.44 0.001**
Duration of HTN (years) 8.40±7.26 5.46±5.67 0.001**
Crcl (ml/min) 57.82±17.41 88.07±24.60 0.001**
FBS (mg/dl) 144.37±31.10 151.13±29.77 0.58
HbA1c (%) 7.68±1.32 7.84±1.35 0.97
SBP (mm/Hg) 137.14±13.51 133.38±12.49 0.01**
DBP (mm/Hg) 81.06±6.29 82.38±5.75 0.05 
Values are expressed as mean±SD *p<0.05; **p<0.01. DM: Diabetes mellitus, 
HTN: Hypertension, FBS: Fasting blood glucose, HbA1c: Hemoglobin A1c, 
SBP:XSystolic blood pressure, DBP: Diastolic blood pressure






Metoprolol 46 (18.25) 15 (17.85) 0.58
Atenolol 58 (23.01) 22 (26.19) 0.66
Bisoprolol 6 (2.38) 2 (2.38) 1.00
Amlodipine 87 (34.52) 24 (28.57) 0.38
Nifedipine 3 (1.19) 3 (3.57) 0.34
Losartan 58 (23.01) 16 (19.04) 0.54
Telmisartan 6 (2.38) 4 (4.76) 0.46
Ramipril 34 (13.49) 11 (13.09) 0.93
Enalapril 67 (26.58) 22 (26.19) 0.94
Hydrochlorothiazide 35 (13.88) 10 (11.90) 0.78
*Total exceeds 100%, since the average patients received more than one drug
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drug to reduce adverse cardiovascular and metabolic events. In the 
present study, with respect to the choice of antihypertensive agents, 
there was no significant difference between geriatrics and non-
geriatrics. Renin-angiotensin aldosterone system inhibitors, namely 
ACE inhibitors (39.9%) and ARBs (25%), were the most commonly 
used antihypertensive agents followed by beta-blockers (44.34%). The 
usage of beta-blockers was more compared to CCBs/diuretics as these 
diabetic hypertensive patients had ischemic heart disease as one of 
the comorbidities. Hence, the prescribing pattern of antihypertensive 
agents in diabetic patients in our study follows the current JNC 8 
guidelines [13]. In contrast, in another study, the most commonly used 
antihypertensives in geriatrics were CCB because the patient population 
was non-diabetics [14]. According to the literature, elderly patients 
require more number of antihypertensive agents compared to their 
younger counterparts [15,16]. However, in the present study, there was 
no significant difference in the number of antihypertensive agents used 
between the groups, which could be due to the reason that combination 
of drugs is probably prescribed in younger adults in whom a tighter 
control of blood pressure is intended compared to geriatrics. It is also 
noteworthy that a combination of four antihypertensive drugs was 
prescribed only for geriatric diabetics. With regard to the combination 
regimen, there is no clear-cut evidence to support the superiority of 
one combination over the others. In our study, ACE inhibitors with 
beta-blockers and/or thiazide diuretics were the most commonly used 
combination.
It is known that beta-blocker responses are blunted with age, and 
hence, higher doses are required in geriatrics. The dosage of beta-
blockers needs to be adapted to GFR [8]. Metoprolol dose appeared 
to be higher in geriatrics (60 vs. 55 mg), whereas atenolol dose lower 
in geriatrics (42 vs. 43 mg) which was statistically and clinically 
insignificant. Hydrophilic beta-blockers (e.g., atenolol, bisoprolol, 
nadolol, and acebutolol) are eliminated renally and dosing adjustments 
are expected in patients with chronic kidney disease [17]; however, 
in our study, there was no reduction in the atenolol dose probably 
because there was only a mild renal impairment (Crcl < 90 ml/min) in 
the geriatric population.
There were no significant differences in the mean converted equivalent 
doses of beta-blockers, CCBs, ARBs, and hydrochlorothiazide when 
adjusted for the duration of hypertension and Crcl in geriatrics and 
non-geriatrics.
ACE inhibitors are widely used as preferred antihypertensive drugs 
for elderly patients with diabetes and nephropathy, due to their 
nephroprotective effect, low risk of hypotension, and metabolic neutrality. 
Several ACE inhibitors (benazepril, ramipril, and fosinopril) cleared by 
kidneys result in an increase in plasma concentration due to CKD or 
age-related renal changes [18]. The mean converted equivalent doses 
of ACE inhibitors were lower in geriatric population (7.2 mg) compared 
to non-geriatric population (8.1 mg), although statistically insignificant 
this difference of 1 mg/day may be clinically significant when we initiate 
therapy. In view of longer duration of hypertension and lower Crcl, ACE 
inhibitor dose needs adjustment for geriatric population. Hence, doses 
were adjusted for the duration of hypertension and Crcl to comprehend 
the true impact of age on doses of ACE inhibitors. When doses of different 
ACE inhibitors are adjusted for the duration of hypertension of 6–7 years, 
a 13–15% reduction was found in geriatric population, and this too was 
statistically insignificant because of a small sample size. A 15–20% dose 
reduction was noted in geriatric patients when adjusted for a Crcl of 
65 ml/min. When both the durations of hypertension and Crcl adjusted 
doses were considered, statistically and clinically significant dosage 
reductions of approximately 20% were noted among geriatric patients 
compared to non-geriatrics. This indicates that geriatric patients require 
an approximately 20% lower dose of ACE inhibitors compared to their 
non-geriatric counterparts; this dose reduction is a function of age and 
is independent of renal function and duration of hypertension. This is 
important clinically because, at the study site, the protocol is to start 
with a lower dose of ACE inhibitors regardless of the age; at other centers 
where the ACE inhibitors are started at a higher dose, the dose reduction 
among geriatrics may be much more.
Most of the commonly used ACE inhibitors are prodrugs which undergo 
activation in the liver. Impaired biotransformation due to hepatic 
dysfunction, often found in the elderly, may require the dose to be 
increased [19]. However, in our study, we found the liver functions of 
the geriatric patients to be within the normal reference range. In our 
previous publication, the doses of sulfonylurea group of oral antidiabetic 
agents required in geriatrics were almost 20–25% less compared to 
non-geriatrics as these drugs are mainly cleared through the kidney 
and also because the geriatric diabetic patients have concealed renal 
impairment compared to non-geriatrics [20]. The present study shows 
that only ACE inhibitors need reduction in drug dosage in geriatrics 
when adjusted for the duration of hypertension and Crcl.
Table 4: Comparison of doses of antihypertensive drugs
Drugs Geriatrics Non‑geriatrics p value
n Doses (mg) n Doses (mg)
Metoprolol 46 61.41±28.72 15 56.66±24.02 0.57
Atenolol 58 42.02±12.97 22 43.18±11.39 0.71
Amlodipine 87 5.17±2.55 24 5.10±2.14 0.97
Losartan 58 40.73±16.97 16 45.31±10.07 0.31
Ramipril 34 3.27±1.71 11 4.09±1.26 0.15
Enalapril 67 7.5±3.50 22 8.21±3.07 0.50
Hydrochlorothiazide 35 14.82±5.26 10 18.25±6.24 0.09
Values are expressed as mean±SD, n=number of patients
Table 5: Comparison of duration and Crcl adjusted dose of antihypertensive drugs in geriatrics and non‑geriatrics
Drug, duration (years), Crcl (ml/min) Geriatrics Non‑geriatrics p Dose: % ↓
n Mean dose±SD (mg) n Mean dose±SD (mg)
Beta-blockers, (8.62), (63.47) 110 38.12±1.51 39 39.25±2.68 0.72 No↓
CCBs, (8.12), (62.95) 90 4.96±0.27 27 4.97±0.51 0.95 No↓
ARBs, (9.37), (60.32) 64 40.12±2.14 20 36.61±4.24 0.48 No↓
Hydrochlorothiazide, (8.96), (59.87) 35 14.78±0.99 10 18.86±1.97 0.08 No↓
Table 6: Comparison of duration and Crcl adjusted dose of ACEIs in geriatrics and non‑geriatrics
Drug, duration (years) Crcl (ml/min) Geriatrics Non‑geriatrics p Dose: % ↓
n Mean dose±SD (mg) n Mean dose±SD (mg)
Enalapril, (6.35), (64.75) 67 7.17±0.42 22 9.04±0.83 0.06 20.57
Ramipril, (6.69), (64.54) 34 3.29±0.29 11 4.03±0.56 0.27 18.36
ACEIs, (6.47), (64.68) 101 7.02±0.34 33 8.64±0.67 0.04* 18.63
*p<0.05, %↓=percentage reduction
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CONCLUSION
Age does not influence drug dosage of antihypertensives except for ACE 
inhibitors. A 20% dosage reduction is needed for ACEIs in the elderly, 
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